Furthermore, in a recent case report a multifocal GBM patient initially received IL13Rα2 CAR T cells via intracavitary infusion to the resected tumor site, which was able to control locoregional progression, but not that of non-resected tumors in the contralateral temporal lobe or the development of new tumors (Brown et al., 2016). This evidence concerns the gene IL13RA2 and neoplasm.